Farallon Capital Management LLC Akebia Therapeutics, Inc. Transaction History

Farallon Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $3.34 Million - $6.79 Million	-500,000 Reduced 40.0%	750,000 $10.2 Million
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $5.13 Million - $12.8 Million	1,250,000 New	1,250,000 $9.48 Million
Q1 2018 May 15, 2018	SELL	$9.53 - $15.68 $7.86 Million - $12.9 Million	-825,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $1.35 Million - $1.86 Million	95,000 Added 13.01%	825,000 $12.3 Million
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $9.53 Million - $14.4 Million	730,000	730,000 $14.4 Million

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.